Ligand Pharmaceuticals Incorporated (LGND) Earnings Call Transcripts

Ligand Pharmaceuticals Incorporated's Latest Earnings Call - April 27, 2026

In the Q1 2026 earnings call, Ligand Pharmaceuticals (LGND:US) announced the acquisition of XOMA Royalty Corporation, a strategic move expected to significantly enhance its royalty portfolio. The company raised its full-year revenue guidance to a range of $270 million to $310 million, up from $245 million to $285 million, and adjusted EPS guidance to $8.50 to $9.50, reflecting a positive impact from the acquisition. This transaction is projected to be immediately accretive to earnings, adding approximately $0.50 to adjusted EPS in 2026 and $1.50 in 2027, marking a strong outlook for future growth.

Reported metrics

Guidance from management

Ligand expects the acquisition of XOMA to be immediately accretive, contributing approximately $0.50 to adjusted EPS in 2026 and $1.50 in 2027. The company raised its revenue and EPS guidance for 2026, reflecting the anticipated impact of the acquisition.

What management said

Thank you, Lauren. We are incredibly excited about this acquisition and the accelerating growth it offers to Ligand. With long-dated royalty cash flow, proprietary financing capabilities and increased financial strength, our position is a next-generation life sciences capital allocator is strengthened. We believe the Ligand strategy and continued execution will continue to deliver compounding profitable growth for ou...

Yes. Yes. On the balance sheet question, we have not disclosed specifically the mix between cash on hand and tapping the credit facility, the revolver. But Joe, I'll just tell you that we have -- as we've stated publicly, we have over $1 billion in deployable capital. We entered the year generating approximately $200 million in operating cash on an annual run rate basis as we exit this year. That will be approaching ...

What analysts pressed on

Analysts expressed concerns regarding the rationale behind an all-cash acquisition given Ligand's stock trading near 52-week highs. They inquired about potential limitations on capital flexibility and how Ligand plans to manage the expanded portfolio of assets post-acquisition.

Main topics on the call

• Acquisition of XOMA Royalty — Ligand announced the acquisition of XOMA Royalty Corporation for $39 per share in cash, which is expected to close in Q3 2026. This acquisition will add seven commercial royalties and over 100 development-stage programs ...
• Guidance Increase — Ligand raised its full-year royalty revenue guidance to $225 million to $250 million, up from $200 million to $225 million. Total revenue guidance was also increased to $270 million to $310 million, reflecting the expect...
• Near-Term Growth Drivers — The acquisition includes key commercial programs such as Vabysmo, Ojemda, and Miplyffa, which are expected to be significant revenue contributors. Analyst peak sales estimates for Vabysmo are $7.5 billion, which could yi...
• Operational and Financial Synergies — Management anticipates significant operational and financial synergies from the integration of XOMA's portfolio, which will enhance Ligand's cash flow generation capabilities. The company expects to realize these synergi...

Read the full Ligand Pharmaceuticals Incorporated transcript (April 27, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 37 Ligand Pharmaceuticals Incorporated earnings call transcripts on record, spanning February 6, 2020 to August 6, 2026. Based on this history, Ligand Pharmaceuticals Incorporated reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

LGND

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

37

First call

February 6, 2020

Most recent

August 6, 2026

Reporting cadence

quarterly